0001209191-20-052460.txt : 20200930 0001209191-20-052460.hdr.sgml : 20200930 20200930163758 ACCESSION NUMBER: 0001209191-20-052460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200928 FILED AS OF DATE: 20200930 DATE AS OF CHANGE: 20200930 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nagendran Sukumar CENTRAL INDEX KEY: 0001665124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 201212657 MAIL ADDRESS: STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD STREET 2: SUITE 160 CITY: BANNOCKBURN STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7318 MORTON STREET CITY: DALLAS STATE: TX ZIP: 75209 BUSINESS PHONE: 212.551.8702 MAIL ADDRESS: STREET 1: 7318 MORTON STREET CITY: DALLAS STATE: TX ZIP: 75209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-28 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001665124 Nagendran Sukumar C/O TAYSHA GENE THERAPIES, INC. 2280 INWOOD ROAD DALLAS TX 75235 1 0 0 0 Common Stock 2020-09-28 4 C 0 19226 A 19226 D Series B Preferred Stock 2020-09-28 4 C 0 17647 0.00 D Common Stock 19226 0 D Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date. /s/ Kamran Alam, Attorney-in-Fact 2020-09-30